RPG Life Sciences quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Year before	Change
Revenue	212	—	—
EBITDA	40.4	—	—
EBITDA margin	19.1%	—	—
Profit before tax	37.0	—	—
Net profit	28.2	—	—
EPS	₹17.07	—	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Earlier quartersAlpha Plus

Expenses
	212	196	177	180	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	4.3	4.7	12.4	3.4
	216	200	189	183
	24.1	37.7	36.4	34.8
	58.7	39.5	22.6	43.6
	−10.7	−9.1	1.5	−13.5
	44.1	37.8	36.3	35.3
	0.8	0.6	0.4	0.3
	6.8	5.9	5.7	5.4
	55.0	46.5	47.2	40.1
	179	159	150	146
	40.4	43.3	32.8	39.8
	33.6	37.4	27.1	34.4
Profit
	37.0	41.5	39.1	37.5
	0.0	0.0	1.1	−8.4
	37.0	41.5	40.2	29.1
	8.7	10.8	7.2	6.9
	0.2	−0.1	3.1	0.1
	8.8	10.7	10.3	7.0
	28.2	30.8	29.9	22.1
	28.2	30.8	29.9	22.1
	−0.2	−0.2	0.1	−0.7
	28.1	30.6	30.0	21.5
	26.6	—	—	—
	1.6	0.0	—	0.0
Per share
	₹17.07	₹18.60	₹18.08	₹13.38
	₹17.07	₹18.60	₹18.08	₹13.38
Other comprehensive income — detail
	−0.2	−0.2	0.1	−0.7
	−0.2	−0.2	0.1	−0.9
	−0.1	−0.1	0.0	−0.2
	26.5	—	—	—
	1.6	—	—	—
Per share — as-filed variants
	₹17.07	₹18.60	₹18.08	₹13.38
	₹17.07	₹18.60	₹0.00	₹0.00
	₹0.00	₹0.00	₹18.08	₹13.38
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	140	128	116	115
	65.9%	65.2%	65.7%	64.0%
Adjusted (ex-exceptional items) — derived
	37.0	41.5	39.1	37.5
	0.0	0.0	1.1	−8.4
	28.2	30.8	29.1	28.5
	₹17.07	₹18.60	₹17.59	₹17.25

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersGUFICBIO GUJTHEM UNICHEMLAB ORCHPHARMA SMSPHARMA FDC IOLCP INDSWFTLABMcap ₹4,703 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	180.0	176.9	195.7	211.6
Other Income	3.4	12.4	4.7	4.3
Total Income	183.4	189.3	200.4	215.9
Expenses
+ Cost of Materials Consumed	34.8	36.4	37.7	24.1
+ Purchases of Stock-in-Trade	43.6	22.6	39.5	58.7
+ Changes in Inventories	-13.5	1.5	-9.1	-10.7
+ Employee Benefit Expense	35.3	36.3	37.8	44.1
+ Finance Costs	0.3	0.4	0.6	0.8
+ Depreciation & Amortisation	5.4	5.7	5.9	6.8
+ Other Expenses	40.1	47.2	46.5	55.0
Total Expenses	145.9	150.2	158.9	178.9
EBITDA	39.8	32.8	43.3	40.4
EBIT	34.4	27.1	37.4	33.6
Profit
PBT before Exceptional Items	37.5	39.1	41.5	37.0
+ Exceptional Items	-8.4	1.1	0.0	0.0
Pretax Income	29.1	40.2	41.5	37.0
+ Current Tax	6.9	7.2	10.8	8.7
+ Deferred Tax	0.1	3.1	-0.1	0.2
Tax Expense	7.0	10.3	10.7	8.8
Net Income	22.1	29.9	30.8	28.2
+ Net Income — Continuing Ops	22.1	29.9	30.8	28.2
+ Other Comprehensive Income	-0.7	0.1	-0.2	-0.2
Total Comprehensive Income	21.5	30.0	30.6	28.1
Net Income to Common	—	—	—	26.6
Minority Interest	0.0	—	0.0	1.6
Per Share
Basic EPS	13.38	18.08	18.60	17.07
Diluted EPS	13.38	18.08	18.60	17.07
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.7	0.1	-0.2	-0.2
+ Items NOT to be Reclassified to P&L	-0.9	0.1	-0.2	-0.2
+ Tax on Items NOT to be Reclassified	-0.2	0.0	-0.1	-0.1
Comprehensive Income — Owners of Parent	—	—	—	26.5
Comprehensive Income — Non-controlling Interests	—	—	—	1.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	13.38	18.08	18.60	17.07
Diluted EPS — Continuing Operations	0.00	0.00	18.60	17.07
Diluted EPS — Discontinued Operations	13.38	18.08	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	115.1	116.3	127.5	139.5
Gross Margin %	63.95	65.75	65.17	65.91
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	37.5	39.1	41.5	37.0
− Exceptional Items (reconciliation)	-8.4	1.1	0.0	0.0
Net Income Adj (tax-effected)	28.5	29.1	30.8	28.2
EPS Adj	17.25	17.59	18.60	17.07
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	8.00	8.00	8.00
Paid Up Equity Capital	13.2	13.2	13.2	13.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

RPG Life Sciences Q2 FY27 results (July–September 2026)

RPG Life Sciences (NSE: RPGLIFE) reported its Q2 FY27 results (July–September 2026). Consolidated net profit attributable to shareholders was ₹26.6 crore, down 13.5% from ₹30.8 crore in Q1 FY27. Revenue from operations was ₹212 crore, up 8.2% from the previous quarter.

Q2 FY26 results (a year earlier): 17 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹26.6 Cr−13.5% vs Q1 FY27Total incl. minority interest ₹28.2 Cr
Revenue from operations: ₹212 Cr+8.2% vs Q1 FY27
Operating margin (EBIT): 15.9%−3.2 pts vs Q1 FY27EBIT ₹33.6 Cr
EBITDA: ₹40.4 Cr−6.6% vs Q1 FY27margin 19.1%
Earnings per share (basic): ₹17.07−8.2% vs Q1 FY27
Net profit margin: 12.6%−3.2 pts vs Q1 FY27

Questions

What was RPG Life Sciences' net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹26.6 crore, down 13.5% from ₹30.8 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹28.2 crore.

What was RPG Life Sciences' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹33.6 crore, a margin of 15.9%, against 19.1% in Q1 FY27. EBITDA was ₹40.4 crore, 19.1% of revenue.

What is RPG Life Sciences' net profit margin?

RPG Life Sciences' net profit margin was 12.6% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations). For FY26 as a whole it was 16.3%.

What was RPG Life Sciences' revenue in Q2 FY27?

Revenue from operations was ₹212 crore, up 8.2% from the previous quarter.

What was RPG Life Sciences' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹115 crore in FY26 (April 2025–March 2026).

What was RPG Life Sciences' revenue in FY26?

Revenue from operations was ₹708 crore in FY26 (April 2025–March 2026).

What was RPG Life Sciences' EPS in Q2 FY27?

Basic earnings per share were ₹17.07.

How has RPG Life Sciences' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹22.1 crore in Q3 FY26, ₹29.9 crore in Q4 FY26, ₹30.8 crore in Q1 FY27 and ₹26.6 crore in Q2 FY27. That is ₹109 crore over the four quarters. Revenue from operations: ₹180 crore, ₹177 crore, ₹196 crore and ₹212 crore.

When will RPG Life Sciences announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these RPG Life Sciences figures come from?

From RPG Life Sciences' own consolidated results filings to NSE, in ₹ crore as filed. Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.